Characteristics of recipients receiving first transplants for acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, or myelodysplastic syndrome with high-resolution HLA typing for HLA-A, -B, -C, and -DRB1 by HLA matching groups that are 7/8 matched or fully (8/8) matched
| Variable . | 7/8 HLA-C*03:03/ C*03:04MM, N (%) . | 7/8 Other HLA-C alleleMM, N (%) . | 7/8 HLA-C antigenMM, N (%) . | 7/8 HLA-A, -B or -DRB1 MM, N (%) . | 8/8 Matched, N (%) . | P . |
|---|---|---|---|---|---|---|
| Patients | 134 | 61 | 700 | 959 | 4779 | |
| Centers | 59 | 36 | 130 | 133 | 162 | |
| Recipient age, median (range), y | 35 (<1-68) | 42 (5-68) | 38 (<1-72) | 37 (<1-74) | 41 (<1-74) | <.0001 |
| Age at transplant, y | <.0001 | |||||
| 0-9 | 17 (13) | 4 (7) | 53 (8) | 93 (10) | 327 (7) | |
| 10-19 | 17 (13) | 4 (7) | 92 (13) | 108 (11) | 430 (9) | |
| 20-29 | 20 (15) | 9 (15) | 94 (13) | 144 (15) | 666 (14) | |
| 30-39 | 23 (17) | 10 (16) | 132 (19) | 183 (19) | 787 (16) | |
| 40-49 | 34 (25) | 12 (20) | 164 (23) | 191 (20) | 1040 (22) | |
| ≥50 | 23 (17) | 22 (36) | 165 (24) | 240 (25) | 1529 (32) | |
| Male sex | 70 (52) | 32 (52) | 387 (55) | 527 (55) | 2712 (57) | .62 |
| Karnofsky prior to transplant ≥90 | 87 (70) | 47 (80) | 472 (72) | 614 (67) | 3065 (69) | .13 |
| Disease at transplant | ||||||
| Acute myeloid leukemia | 51 (38) | 22 (36) | 276 (39) | 385 (40) | 1952 (41) | .13 |
| Acute lymphoblastic leukemia | 31 (23) | 17 (28) | 157 (22) | 207 (22) | 920 (19) | |
| Chronic myeloid leukemia | 34 (25) | 11 (18) | 158 (23) | 217 (23) | 1021 (21) | |
| Myelodysplastic syndrome | 18 (13) | 11 (18) | 109 (16) | 150 (16) | 886 (19) | |
| Disease status at transplant | ||||||
| Early | 98 (73) | 43 (70) | 472 (67) | 658 (69) | 3363 (70) | .30 |
| Intermediate | 5 (4) | 5 (8) | 36 (5) | 62 (6) | 228 (5) | |
| Advanced | 31 (23) | 13 (21) | 192 (27) | 239 (25) | 1188 (25) | |
| Conditioning regimen | ||||||
| Myeloablative | 113 (84) | 38 (62) | 583 (83) | 781 (81) | 3672 (77) | <.0001 |
| RIC/nonmyeloablative | 21 (16) | 23 (38) | 117 (17) | 178 (19) | 1107 (23) | |
| Graft type | ||||||
| Bone marrow | 83 (62) | 34 (56) | 446 (64) | 590 (62) | 2660 (56) | <.0001 |
| Peripheral blood stem cells | 51 (38) | 27 (44) | 254 (36) | 369 (38) | 2119 (44) | |
| Antigen vs allele mismatching | <.0001 | |||||
| Fully matched (8/8) | 0 | 0 | 0 | 0 | 4779 | |
| Single allele mismatch | 134 | 61 | 0 | 514 (54) | 0 | |
| Single antigen mismatch | 0 | 0 | 700 | 445 (46) | 0 | |
| HLA group 8/8 matched | 0 | 0 | 0 | 0 | 4779 (100) | <.0001 |
| 7/8 with MM at HLA-A | 0 | 0 | 0 | 495 (52) | 0 | |
| 7/8 with MM at HLA-B | 0 | 0 | 0 | 261 (27) | 0 | |
| 7/8 with MM at HLA-C | 134 (100) | 61 (100) | 700 (100) | 0 | 0 | |
| 7/8 with MM at HLA-DRB1 | 0 | 0 | 0 | 203 (21) | 0 | |
| GVHD prophylaxis | <.0001 | |||||
| FK506 ± other | 55 (41) | 31 (51) | 282 (40) | 391 (41) | 2299 (48) | |
| CsA ± MTX ± other | 68 (51) | 24 (39) | 351 (50) | 454 (47) | 2142 (45) | |
| Other | 11 (8) | 6 (10) | 67 (10) | 114 (12) | 338 (7) | |
| Donor/recipient cytomegalovirus match | ||||||
| Negative/negative | 53 (40) | 25 (41) | 228 (33) | 324 (34) | 1600 (33) | .08 |
| Negative/positive | 37 (28) | 20 (33) | 209 (30) | 283 (30) | 1539 (32) | |
| Positive/negative | 22 (16) | 6 (10) | 102 (15) | 151 (16) | 624 (13) | |
| Positive/positive | 18 (13) | 9 (15) | 141 (20) | 164 (17) | 793 (17) | |
| Unknown | 4 (3) | 1 (2) | 20 (3) | 37 (4) | 223 (5) | |
| HLA-DQB1 typing | <.0001 | |||||
| Fully matched | 114 (85) | 60 (98) | 616 (88) | 800 (83) | 4411 (92) | |
| Single DQB1 mismatch | 20 (15) | 1 (2) | 84 (12) | 159 (17) | 368 (8) | |
| Double DQB1 mismatch | 0 | 0 | 0 | 0 | 0 | |
| HLA-DPB1 typing | .08 | |||||
| Fully matched | 6 (8) | 5 (15) | 61 (14) | 69 (12) | 368 (15) | |
| Single DPB1 mismatch | 51 (65) | 13 (38) | 240 (54) | 301 (54) | 1387 (56) | |
| Double DPB1 mismatch | 21 (27) | 16 (47) | 145 (33) | 188 (34) | 740 (30) | |
| Missing DPB1 typing | 56 | 27 | 254 | 401 | 2284 | |
| Donor/recipient sex match | ||||||
| Male/male | 47 (35) | 18 (30) | 246 (35) | 333 (35) | 1952 (41) | <.0001 |
| Male/female | 37 (28) | 12 (20) | 171 (24) | 228 (24) | 1249 (26) | |
| Female/male | 23 (17) | 14 (23) | 141 (20) | 194 (20) | 760 (16) | |
| Female/female | 27 (20) | 17 (28) | 142 (20) | 204 (21) | 818 (17) | |
| Donor age, median (range), y | 37 (19-57) | 36 (21-58) | 36 (19-61) | 37 (19-60) | 34 (18-61) | <.0001 |
| Donor age | <.0001 | |||||
| 18-29 | 35 (26) | 17 (28) | 171 (24) | 223 (23) | 1606 (34) | |
| 30-39 | 38 (28) | 21 (34) | 276 (39) | 368 (38) | 1734 (36) | |
| 40-49 | 48 (36) | 21 (34) | 199 (28) | 279 (29) | 1161 (24) | |
| 50 and older | 13 (10) | 2 (3) | 54 (8) | 89 (9) | 278 (6) | |
| Year of transplant | <.0001 | |||||
| 1988-1994 | 21 (16) | 3 (5) | 84 (12) | 148 (15) | 490 (10) | |
| 1995-2000 | 42 (31) | 16 (26) | 235 (34) | 243 (25) | 1078 (23) | |
| 2001-2004 | 34 (25) | 19 (31) | 199 (28) | 236 (25) | 1159 (24) | |
| 2005-2009 | 37 (28) | 23 (38) | 182 (26) | 332 (35) | 2052 (43) | |
| Median follow up of recipients, mo (range) | 84 (12-234) | 66 (11-156) | 96 (3-229) | 79 (11-240) | 69 (3-264) | <.0001 |
| Variable . | 7/8 HLA-C*03:03/ C*03:04MM, N (%) . | 7/8 Other HLA-C alleleMM, N (%) . | 7/8 HLA-C antigenMM, N (%) . | 7/8 HLA-A, -B or -DRB1 MM, N (%) . | 8/8 Matched, N (%) . | P . |
|---|---|---|---|---|---|---|
| Patients | 134 | 61 | 700 | 959 | 4779 | |
| Centers | 59 | 36 | 130 | 133 | 162 | |
| Recipient age, median (range), y | 35 (<1-68) | 42 (5-68) | 38 (<1-72) | 37 (<1-74) | 41 (<1-74) | <.0001 |
| Age at transplant, y | <.0001 | |||||
| 0-9 | 17 (13) | 4 (7) | 53 (8) | 93 (10) | 327 (7) | |
| 10-19 | 17 (13) | 4 (7) | 92 (13) | 108 (11) | 430 (9) | |
| 20-29 | 20 (15) | 9 (15) | 94 (13) | 144 (15) | 666 (14) | |
| 30-39 | 23 (17) | 10 (16) | 132 (19) | 183 (19) | 787 (16) | |
| 40-49 | 34 (25) | 12 (20) | 164 (23) | 191 (20) | 1040 (22) | |
| ≥50 | 23 (17) | 22 (36) | 165 (24) | 240 (25) | 1529 (32) | |
| Male sex | 70 (52) | 32 (52) | 387 (55) | 527 (55) | 2712 (57) | .62 |
| Karnofsky prior to transplant ≥90 | 87 (70) | 47 (80) | 472 (72) | 614 (67) | 3065 (69) | .13 |
| Disease at transplant | ||||||
| Acute myeloid leukemia | 51 (38) | 22 (36) | 276 (39) | 385 (40) | 1952 (41) | .13 |
| Acute lymphoblastic leukemia | 31 (23) | 17 (28) | 157 (22) | 207 (22) | 920 (19) | |
| Chronic myeloid leukemia | 34 (25) | 11 (18) | 158 (23) | 217 (23) | 1021 (21) | |
| Myelodysplastic syndrome | 18 (13) | 11 (18) | 109 (16) | 150 (16) | 886 (19) | |
| Disease status at transplant | ||||||
| Early | 98 (73) | 43 (70) | 472 (67) | 658 (69) | 3363 (70) | .30 |
| Intermediate | 5 (4) | 5 (8) | 36 (5) | 62 (6) | 228 (5) | |
| Advanced | 31 (23) | 13 (21) | 192 (27) | 239 (25) | 1188 (25) | |
| Conditioning regimen | ||||||
| Myeloablative | 113 (84) | 38 (62) | 583 (83) | 781 (81) | 3672 (77) | <.0001 |
| RIC/nonmyeloablative | 21 (16) | 23 (38) | 117 (17) | 178 (19) | 1107 (23) | |
| Graft type | ||||||
| Bone marrow | 83 (62) | 34 (56) | 446 (64) | 590 (62) | 2660 (56) | <.0001 |
| Peripheral blood stem cells | 51 (38) | 27 (44) | 254 (36) | 369 (38) | 2119 (44) | |
| Antigen vs allele mismatching | <.0001 | |||||
| Fully matched (8/8) | 0 | 0 | 0 | 0 | 4779 | |
| Single allele mismatch | 134 | 61 | 0 | 514 (54) | 0 | |
| Single antigen mismatch | 0 | 0 | 700 | 445 (46) | 0 | |
| HLA group 8/8 matched | 0 | 0 | 0 | 0 | 4779 (100) | <.0001 |
| 7/8 with MM at HLA-A | 0 | 0 | 0 | 495 (52) | 0 | |
| 7/8 with MM at HLA-B | 0 | 0 | 0 | 261 (27) | 0 | |
| 7/8 with MM at HLA-C | 134 (100) | 61 (100) | 700 (100) | 0 | 0 | |
| 7/8 with MM at HLA-DRB1 | 0 | 0 | 0 | 203 (21) | 0 | |
| GVHD prophylaxis | <.0001 | |||||
| FK506 ± other | 55 (41) | 31 (51) | 282 (40) | 391 (41) | 2299 (48) | |
| CsA ± MTX ± other | 68 (51) | 24 (39) | 351 (50) | 454 (47) | 2142 (45) | |
| Other | 11 (8) | 6 (10) | 67 (10) | 114 (12) | 338 (7) | |
| Donor/recipient cytomegalovirus match | ||||||
| Negative/negative | 53 (40) | 25 (41) | 228 (33) | 324 (34) | 1600 (33) | .08 |
| Negative/positive | 37 (28) | 20 (33) | 209 (30) | 283 (30) | 1539 (32) | |
| Positive/negative | 22 (16) | 6 (10) | 102 (15) | 151 (16) | 624 (13) | |
| Positive/positive | 18 (13) | 9 (15) | 141 (20) | 164 (17) | 793 (17) | |
| Unknown | 4 (3) | 1 (2) | 20 (3) | 37 (4) | 223 (5) | |
| HLA-DQB1 typing | <.0001 | |||||
| Fully matched | 114 (85) | 60 (98) | 616 (88) | 800 (83) | 4411 (92) | |
| Single DQB1 mismatch | 20 (15) | 1 (2) | 84 (12) | 159 (17) | 368 (8) | |
| Double DQB1 mismatch | 0 | 0 | 0 | 0 | 0 | |
| HLA-DPB1 typing | .08 | |||||
| Fully matched | 6 (8) | 5 (15) | 61 (14) | 69 (12) | 368 (15) | |
| Single DPB1 mismatch | 51 (65) | 13 (38) | 240 (54) | 301 (54) | 1387 (56) | |
| Double DPB1 mismatch | 21 (27) | 16 (47) | 145 (33) | 188 (34) | 740 (30) | |
| Missing DPB1 typing | 56 | 27 | 254 | 401 | 2284 | |
| Donor/recipient sex match | ||||||
| Male/male | 47 (35) | 18 (30) | 246 (35) | 333 (35) | 1952 (41) | <.0001 |
| Male/female | 37 (28) | 12 (20) | 171 (24) | 228 (24) | 1249 (26) | |
| Female/male | 23 (17) | 14 (23) | 141 (20) | 194 (20) | 760 (16) | |
| Female/female | 27 (20) | 17 (28) | 142 (20) | 204 (21) | 818 (17) | |
| Donor age, median (range), y | 37 (19-57) | 36 (21-58) | 36 (19-61) | 37 (19-60) | 34 (18-61) | <.0001 |
| Donor age | <.0001 | |||||
| 18-29 | 35 (26) | 17 (28) | 171 (24) | 223 (23) | 1606 (34) | |
| 30-39 | 38 (28) | 21 (34) | 276 (39) | 368 (38) | 1734 (36) | |
| 40-49 | 48 (36) | 21 (34) | 199 (28) | 279 (29) | 1161 (24) | |
| 50 and older | 13 (10) | 2 (3) | 54 (8) | 89 (9) | 278 (6) | |
| Year of transplant | <.0001 | |||||
| 1988-1994 | 21 (16) | 3 (5) | 84 (12) | 148 (15) | 490 (10) | |
| 1995-2000 | 42 (31) | 16 (26) | 235 (34) | 243 (25) | 1078 (23) | |
| 2001-2004 | 34 (25) | 19 (31) | 199 (28) | 236 (25) | 1159 (24) | |
| 2005-2009 | 37 (28) | 23 (38) | 182 (26) | 332 (35) | 2052 (43) | |
| Median follow up of recipients, mo (range) | 84 (12-234) | 66 (11-156) | 96 (3-229) | 79 (11-240) | 69 (3-264) | <.0001 |
CsA, cyclosporine A; MTX, methotrexate; RIC, reduced intensity conditioning.